Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 14/20 | 0.72 |
| ▸ | PIK3CD | O00329 | 10/20 | 0.72 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.72 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.72 |
| ▸ | JAK2 | O60674 | 3/20 | 0.54 |
| ▸ | TTK | P33981 | 1/20 | 0.51 |
| ▸ | JAK3 | P52333 | 2/20 | 0.50 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.50 |
| ▸ | DHFR | P00374 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27038303 | 0.88 | PIK3CG (0.63) | PIK3CGPIK3CDPIK3CAPIK3CBJAK2 | |
| SCHEMBL937217 | 0.87 | PIK3CG (0.59) | PIK3CGPIK3CDPIK3CAPIK3CB | |
| SCHEMBL936107 | 0.85 | PIK3CG (0.72) | PIK3CGPIK3CDPIK3CAPIK3CBJAK2 | |
| SCHEMBL936625 | 0.84 | PIK3CG (1.00) | PIK3CGPIK3CDPIK3CAPIK3CB | |
| SCHEMBL1933137 | 0.79 | PIK3CG (0.52) | PIK3CGPIK3CDPIK3CAPIK3CBPTK2 | |
| SCHEMBL614711 | 0.78 | RET (0.61) | PIK3CGPIK3CDPIK3CAPIK3CBJAK2 | |
| SCHEMBL939045 | 0.76 | PIK3CG (0.54) | PIK3CGPIK3CDPIK3CAPIK3CBJAK2 | |
| SCHEMBL12909565 | 0.76 | PIK3CG (0.50) | PIK3CGPIK3CDPIK3CAPIK3CBPTK2 | |
| SCHEMBL936706 | 0.76 | PIK3CG (0.58) | PIK3CGPIK3CDPIK3CAPIK3CB | |
| SCHEMBL30868048 | 0.76 | PIK3CG (0.50) | PIK3CGPIK3CDPIK3CAPIK3CBTTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633173-B2 | Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives | CEPHALON, INC (US) | 2014-01-21 | — | — | US | disclosed |
| US-20130296312-A1 | Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives | CEPHALON, INC. | 2013-11-07 | — | — | US | disclosed |
| US-8501936-B2 | Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives | CEPHALON, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| EP-2438066-A2 | PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a]PYRIDINE DERIVATIVES | Cephalon, Inc. (US) | 2012-04-11 | — | — | EP | disclosed |
| US-20100311693-A1 | Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives | CEPHALON, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| WO-2010141796-A2 | PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES | CEPHALON, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296312-A1 | Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives | JAK2, JAK1, JAK3 | PIK3CG 650/4885PIK3CD 1022/4885PIK3CA 339/4885 |
| US-20100311693-A1 | Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives | CCNA1, CCNY, RB1 | PIK3CG 1765/4885PIK3CD 2049/4885PIK3CA 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.